Scientists explore potential of synthetic CBD for pain management

A company which creates synthetic cannabinoids is teaming up with world-class scientists to evaluate the effectiveness of its products in the treatment of pain and opioid addiction.

Therapeutic cannabinoid company, Nalu Bio, has announced a collaboration with Ken Mackie, M.D, chair and distinguished Professor at Indiana University’s Gill Center for Biomolecular Science.

Together, the team will evaluate how the potency and efficacy of the company’s proprietary synthetic cannabinoids – specifically its CBD – may enable the development of effective non-opioid pain management.

Nalu Bio has developed a proprietary chemistry platform that enables highly efficient commercial production of organically synthesised cannabinoids. 

The company is creating a new category of cannabinoids and wellness ingredients which will offer great therapeutic promise for the treatment of pain management and opioid addiction. 

The collaboration with Prof Mackie aims to demonstrate that synthetic CBD has the same potency and efficacy as plant-derived CBD.

Nalu Bio’s platform eliminates any potential for THC generation, biological variability, unwanted contaminants, as well as the high-capital costs inherent in complex hemp extraction. 

The process reliably delivers consistent, scalable, sustainable and cost-effective CBD with each and every batch. 

Given these advantages, Nalu Bio will be well-positioned to establish an expanded pipeline of safer, purer and consistently performing cannabinoids for the wellness and therapeutics markets.

“I am excited to be working with Nalu Bio and their exceptional team of healthcare professionals to bring a new category of chemistry-derived cannabinoids to patients and consumers worldwide, enabling effective pain management with non-opioid solutions, said Prof Mackie.

Caitlyn Krebs, co-founder and CEO of Nalu Bio, added: “Ken and the Gill Center are world renowned for their understanding of the endocannabinoid system, which they’ve been studying since it was discovered in the 1980’s. 

“We are very excited to be working with these distinguished scientists to help us realize the full therapeutic potential of synthetic cannabinoids. We are especially pleased to welcome Ken to our Advisory Board.”